


## A few examples in the pharmaceuticals and biotechnologies sector

 <b>ZIMMER BIOMET</b>	<p><b>ZIMMER BIOMET (UNITED STATES)</b>          Zimmer Biomet, an American manufacturer of robotic surgical assistance devices, which invested €20 million to expand its production facility in Occitanie near Montpellier-Méditerranée Airport, and plans to create 54 jobs.</p>
	<p><b>VIVITRO LABS (CANADA)</b>          Vivitro Labs, a subsidiary of the Canadian group Starfish Medical based in Victoria (British Columbia), develops equipment for the testing of cardiovascular and endovascular medical devices, offering associated services. After several successful collaborations with the Marseille-based firm ProtomedLabs, which employs five people, Vivitro Labs strengthened its European development with the acquisition of ProtomedLabs, a French business, to develop its operations internationally.</p>
	<p><b>INOVET (BELGIUM)</b>          The veterinary pharmaceutical company Biové, owned by Belgian group InoVet, which is located in Arques in Hauts de France, will benefit from an investment of €28 million to triple the capacity of its production site. The new investment, divided into four phases, will be used to modernize the factory and to triple production capacity. InoVet is targeting entry into the world's top 50 animal health companies (livestock and domestic) by 2024.</p>
	<p><b>CHIESI FARMACEUTICI (ITALY)</b>          The expansion project of the La Chaussée-Saint-Victor industrial site (Centre-Val de Loire region) announced in July 2019 by the Chiesi Farmaceutici Spa laboratory is part of the Italian group's social and environmental responsibility strategy. Chiesi is the first pharmaceutical laboratory to receive B Corp certification, which rewards its commitment to social and environmental responsibility and carbon neutrality by 2035. The Italian group wants the La Chaussée-Saint-Victor site to become a technological and strategic platform for the environment, for its customers and for its employees.</p>
 TAISHO PHARMACEUTICAL	<p><b>TAISHO PHARMACEUTICAL HOLDINGS (JAPAN)</b>          Taisho Pharmaceutical Holdings is the largest Japanese firm for over-the-counter drugs, including anti-inflammatory drugs for the treatment of colds and flu, and is the leader for this type of product in Japan, ranked eighth in the world. Taisho Pharmaceutical Holdings announced the acquisition of UPSA, the French subsidiary of the American group Bristol-Myers Squibb, on July 1, 2019. This business, specializing in anti-inflammatory drugs, including Dafalgan, Efferalgan and Fervex for the treatment of colds and flu, is ranked second for the sale of over-the-counter drugs in France. It employs 1,300 people across its two production sites located in Agen (Nouvelle Aquitaine) and 250 in its head office in Rueil-Malmaison, near Paris (Ile de France). This investment, which will see UPSA's brand and identity maintained, will enable Taisho Pharmaceutical Holdings to have its first industrial base in Europe.</p>
	<p><b>CELLTRION HEALTHCARE (SOUTH KOREA)</b>          After opening a branch in 2018, the leading South Korean producer of biosimilars and innovative medicines decided to create a sales and marketing office in Paris to strengthen its operations and to develop its own sales network in the French market. Already a leader in the infliximab market in Europe, Celltrion intends to expand its product portfolio with value-added and bioinnovative medicines, creating around ten jobs through this expansion.</p>